Investing.com -- Acrivon Therapeutics Inc (NASDAQ:ACRV) stock plummeted 29.2% Thursday after the clinical-stage biotech company released mixed results from its ongoing cancer treatment trials.

Acrivon Therapeutics Inc (NASDAQ:ACRV) shares tumbled 29.2% on Thursday after the clinical-stage biotechnology company disclosed a mixed set of results from its ongoing cancer studies, which appeared ...

Biopsy from a patient with collision type mixed ductal-lobular breast cancer, showing ductal cancer cells in blue and lobular cells in red. As part of a breast cancer diagnosis, pathologists take ...

AIM high: Epigenetic modulation and immune stimulation in bladder cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...